Observations placeholder

Oxybutynin (Ditropan, Lyrinel XL, Lenditro (South Africa), Uripan (Middle East) is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination (urge incontinence), by decreasing muscle spasms of the bladder

Adverse effects

Common adverse effects associated with oxybutynin and other anticholinergics include: dry mouth, difficulty in urination, constipation, blurred vision, drowsiness, and dizziness Anticholinergics have also been known to induce delirium.

These are dose-related and sometimes severe. In one population studied—after six months, more than half of the patients had stopped taking the medication because of side effects and calcium defects. An intake of calcium of 800 to 1000 mg is suggested.[citation needed] Dry mouth may be particularly severe; one estimate is that over a quarter of patients who begin oxybutynin treatment may have to stop because of dry mouth.[citation needed]

N-Desethyloxybutynin is an active metabolite of oxybutynin that is thought responsible for much of the adverse effects associated with the use of oxybutynin N-Desethyloxybutynin plasma levels may reach as much as six times that of the parent drug after administration of the immediate-release oral formulation. Alternative dosage forms have been developed in an effort to reduce blood levels of N-desethyloxybutynin and achieve a steadier concentration of oxybutynin than is possible with the immediate release form. The long-acting formulations also allow once-daily administration instead of the twice-daily dosage required with the immediate-release form. The transdermal patch, in addition to the benefits of the extended-release oral formulations, bypasses the first-pass hepatic effect that the oral formulations are subject to. In those with overflow incontinence because of diabetes or neurological diseases like multiple sclerosis or spinal cord trauma, oxybutynin can worsen overflow incontinence since the fundamental problem is that the bladder is not contracting.

A large study linked the development of Alzheimer's disease and other forms of dementia in those over 65 to the use of oxybutynin, due to its anticholinergic properties.

Time on Oxybutynin chloride when people have Hallucination  :

Age of people who have Hallucination when taking Oxybutynin chloride  :

On Jan, 10, 2016: 2,669 people reported to have side effects when taking Oxybutynin chloride. Among them, 35 people (1.31%) have Death.

Time on Oxybutynin chloride when people have Death  :

Age of people who have Death when taking Oxybutynin chloride  :

Top conditions involved for these people  :

1. Pain (10 people, 28.57%)
2. Anxiety (9 people, 25.71%)